Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,880.00p
   
  • Change Today:
    -11.00p
  • 52 Week High: 2,205.00p
  • 52 Week Low: 1,722.00p
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 6,229
  • Market Cap: £4,171.44m
  • RiskGrade: 125

Hikma Pharmaceuticals US subsidiary launches GERD treatment

By Michele Maatouk

Date: Monday 30 Oct 2017

LONDON (ShareCast) - (ShareCast News) - Hikma Pharmaceuticals' wholly-owned US subsidiary, West-Ward Pharmaceuticals, has launched pantoprazole sodium for injection, 40mg, in the US for the short-term treatment of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis.
According to IMS Health, US sales of pantoprazole sodium for injection were around $104m in the 12 months ending August 2017.

Riad Mechlaoui, Hikma's chief executive officer of Injectables, said: "We are very pleased to launch pantoprazole sodium for injection, reducing the shortage of this product in the US market. We are successfully executing our injectables pipeline and leveraging the additional capacity we have been adding to our Portuguese facility to support future growth."

At 1125 BST, the shares were up 0.1% to 1,124p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,880.00p
Change Today -11.00p
% Change -0.58 %
52 Week High 2,205.00p
52 Week Low 1,722.00p
Volume 6,229
Shares Issued 221.89m
Market Cap £4,171.44m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average
1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average
Price Trend
44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 01-Jul-2024

Time Volume / Share Price
08:58 103 @ 1,880.00p
08:58 2 @ 1,880.00p
08:58 45 @ 1,880.00p
08:55 25 @ 1,882.00p
08:55 24 @ 1,881.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page